Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
If you are on the fence about what to do with your GSK shares, you are not alone. The stock has seen some interesting moves ...
GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock ...
Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...
GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term ...
Zacks Investment Research on MSN

Why GSK (GSK) is a Top Growth Stock for the Long-Term

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
There’s a lot of froth in the stock market right now. Yet at the same time, there are also a lot of bargains for long-term investors. The post While there are bubbles in the stock market, this sector ...
GSK (NYSE:GSK – Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect GSK to post earnings of $1.06 per share and revenue ...